Granulocyte/Monocyte Adsorptive Apheresis in Moderate to Severe XXXX --Effective or Not?

@entity1 @entity1066 @entity31
BACKGROUND AND AIMS: Adsorptive granulocyte/monocyte apheresis (GMA) has shown promising efficacy in the treatment of @entity1 with @entity31 ( @entity31 ). But a sham-controlled study was negative. A post-hoc analysis of this trial may haul out @entity1 responding to GMA. METHODS: A total of 168 @entity31 @entity1 with a disease activity (DAI) between 6 and 11 were enrolled in this study. Out of 168 @entity1 , 112 received GMA and 56 sham apheresis. The basis for this post hoc analysis is the clinical study report issued by Otsuka America Pharmaceutical. RESULTS: Baseline histology was available for 165 @entity1 . Only 38% (63 of 165) of @entity1 showed microscopic erosion/ @entity1066 (group P). The remaining 62% of @entity1 did not show microscopic erosion/ @entity1066 (group A). The @entity1 in group P showed significantly higher DAI, flexible proctosigmoidoscopy score and neutrophil infiltration into the colonic mucosa than those in group A (p = 0.0132, p = 0.0243 and p < 0.0001, respectively). Likewise, group P @entity1 had a significantly (p = 0.0275) higher remission rate (11 of 46; 23.9%) when treated with GMA than with sham procedure (0 of 17; 0%). CONCLUSIONS: @entity1 in group P who had more active @entity31 than those in group A showed clear clinical efficacy in response to GMA. We believe that true DAI should be specified for further randomized controlled trials.
